modelJ07BB02
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | InfluenzaInactivatedSplitVirusOrSurfaceAntigen | |
| ATC code: | J07BB02 | route: | intramuscular |
| compartments: | 1 | |
| dosage: | 15 | mg |
| volume of distribution: | 1 | L |
| clearance: | 0 | L/hr |
| other parameters in model implementation | ||
Influenza, inactivated, split virus or surface antigen vaccines are used to prevent influenza (flu) caused by influenza viruses. These vaccines contain inactivated (killed) influenza viruses and are often split or contain only the surface antigens to minimize side effects. They are administered annually and are approved for use in most countries for the prevention of seasonal influenza.
Pharmacokinetics
No direct pharmacokinetic data published for inactivated, split virus or surface antigen influenza vaccines in humans. As these are vaccines, they are not absorbed, distributed, metabolized, or eliminated in the same way as traditional small-molecule drugs; rather, they elicit an immune response at the injection site.
References
Hodges, TL, et al., & Izu, AE (1991). Phase 1 study of recombinant human CD4-immunoglobulin G therapy of patients with AIDS and AIDS-related complex. Antimicrobial agents and chemotherapy 35(12) 2580–2586. DOI:10.1128/AAC.35.12.2580 PUBMED:https://pubmed.ncbi.nlm.nih.gov/1810192
Kahn, JO, et al., & Groopman, JE (1990). The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study. Annals of internal medicine 112(4) 254–261. DOI:10.7326/0003-4819-112-4- PUBMED:https://pubmed.ncbi.nlm.nih.gov/2297204
Ortonne, JP (2003). Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. Journal of the European Academy of Dermatology and Venereology : JEADV 17 Suppl 2 12–16. DOI:10.1046/j.1468-3083.17.s2.3.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/12795770
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)